Our study indicates that SR-B1 loss-of-function mutant carriers might be susceptible to developing metabolic nephropathy in addition to cardiovascular diseases, and probucol might be a potential therapeutics. This evidence concerns the gene SCARB1 and cardiovascular disorder.